ReviewTherapeutic advances in hematology2022

Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.

Jérôme Paillassa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.